Chargement en cours...
Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: evidence to date
Immune checkpoint inhibitors (ICI) as monotherapy in selected patients as well as in combination with chemotherapy have become the standard of care in the first-line treatment strategy of advanced non-small cell lung cancer (NSCLC) patients. Combination treatment with ICI, such as nivolumab and ipil...
Enregistré dans:
| Publié dans: | Cancer Manag Res |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6549681/ https://ncbi.nlm.nih.gov/pubmed/31213908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S164935 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|